Table 1.
Subjects (patients) | Dose (ppm) | Number/time of action | Total days | Existing/possible results | Ref/NCT/EUCTR |
---|---|---|---|---|---|
Moderate/severe (200) | 80 → 40 | All day | 2 | Arterial oxygen saturation increased about 20% | 04306393 87a |
ICU (20) | 160 | 6 h/day once a day | 2 | High dose iNO could have beneficial effects | 04383002 |
Severe (100) | 1–80 | / | / | Reduced organ damage, mechanical ventilation, death | 2020-001329-30-AT |
Moderate/severe (42) | 20 | 1.5 times/hour | 14 | Reduced progressive systemic deoxygenation, intubation, or death | 04388683b |
Moderate/severe (20) | 160 | / | 26 | Reduced oxygen therapy, BIPAP, CPAP, intubation, mechanical ventilationc | 03331445a |
Severe pregnant (6) | 160 → 200 | twice a day | <17 | Improved cardiopulmonary function, newborns were in good condition | 90a |
Mild (260) | 140 → 300 | 20–30 min/time | / | Improved short term respiratory status, prevent hospitalization | 04338828 |
Mild/moderate (67) | 140 → 180 | 20–30 min/time twice a day | 14 | iNO has beneficial effects | 04305457 |
Mild (300) | / | Nasal Spray + Nasal Irrigation/day | 14 | Treat and prevent exacerbation | 04443868 |
Mild (240) | 140 → 180 | 20–30min/time twice a day | 28 | Safely slow down or stop deterioration | 91a |
Mild (20) | 200/200 + 20 | 30 min/time twice a day (20 ppm all day) | 14 | Improved oxygenation | 04476992a |
Mild (39) | 30(start) | Up or down through the course of disease | 2.1 | Reduced endotracheal intubation (53.9%), improved oxygenation | 92 |
Mild (female) | 20/day 10 → 0/night |
12–14 h/day (2 h/night) | 10 | Progressive dyspnea and fatigue etc. Completely disappeared | 93a |
Close contacts (470) | 160 | 30 min/times twice a day | 14 | Reduce the incidence to 5% | 04312243 95a |
Close contacts (200) | / | NOG/morning NONI/evening NONS<5 times/dayb |
14 | Inactivate SARS-CoV-2 | 04337918 |
Mild (50) | 80/150 | 40 min/time four times/day | <14 | / | 04456088 |
All (20) | 80 | 40 min/time four times/day | / | 04397692 | |
Moderate/severe (500) | 20 | All day | <14 | INOpulse is safe and effective | 04421508 |
Mild/moderate | 20 | 8–24 h/day | / | INOpulse is safe and effective | 2020-002394-94-BE |
Levels of NO2 (<2 ppm) or methemoglobin (<5%) are closely monitored throughout the experiment.
Nitric Oxide Gargle (NOG), Nitric Oxide Nasophyaryngeal Irrigation (NONI), Nitric Oxide Nasal Spray (NONS).
Biphasic intermittent positive airway pressure (BIPAP), continuous positive airway pressure (CPAP).